SeaStar Medical (ICU) vs Polyrizon (PLRZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Polyrizon (PLRZ) has outperformed SeaStar Medical (ICU) over the past year, gaining 23.2% versus a loss of 47.0%. Polyrizon is the larger company by market cap ($22.1 million vs $17.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICU | PLRZ |
|---|---|---|
| Share price | $3.40 | $9.10 |
| Market cap | $17.88M | $22.09M |
| 1-day change | -2.63% | +2.59% |
| YTD return | +45.42% | +4.48% |
| 1-year return | -47.04% | +23.19% |
| 5-year return | -99.86% | — |
| EPS (TTM) | $-2.97 | $-4.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.35 | $18.20 |
| 52-week low | $2.07 | $2.88 |
| Distance from 52-week high | -53.76% | -50.01% |
| Analyst consensus | none | — |
| Avg. price target upside | +194.26% | — |
| Average volume | 99.80K | 60.55K |
| Shares outstanding | 5.26M | 2.43M |
| Employees | 18 | 2 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRZ has outperformed ICU by 70.2 percentage points over the past year.
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Health Care · Medical/Dental Instruments · 18 employees
About Polyrizon
PLRZ stock →Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
Health Care · Medical/Dental Instruments · 2 employees
ICU vs PLRZ FAQ
Which is bigger, SeaStar Medical or Polyrizon?
Polyrizon (PLRZ) is larger, with a market capitalization of $22.09M compared with $17.88M for SeaStar Medical (ICU).
Which stock has performed better over the past year, ICU or PLRZ?
PLRZ returned +23.19% over the past 12 months, compared with -47.04% for ICU (price return, excluding dividends). Past performance does not predict future results.
Are SeaStar Medical and Polyrizon in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.